Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

RE de Feria Cardet; MS Hofman; T Segard; J Yim; S Williams; RJ Francis; M Frydenberg; N Lawrentschuk; DG Murphy; R De Abreu Lourenco

Journal article

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial

RE de Feria Cardet, MS Hofman, T Segard, J Yim, S Williams, RJ Francis, M Frydenberg, N Lawrentschuk, DG Murphy, R De Abreu Lourenco

European Urology | ELSEVIER | Published : 2021

DOI: 10.1016/j.eururo.2020.11.043

Abstract

Background: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use. Objective: To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging. Design, setting, and participants: A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or 68Ga-PSMA-11 PET/CT with planned health economics data collected. The cost-effectiveness analysis was conducted from an Australian societal perspective. Inte..

View full abstract

University of Melbourne Researchers

Michael Hofman Author

Scott Williams Author

Nathan Lawrentschuk Author

Declan Murphy Author

Grants

Funding Acknowledgements

This investigator-initiated trial was funded by Movember and the Prostate Cancer Foundation of Australia and co-badged by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. The sponsor (Peter MacCallum Cancer Centre) and funders had no direct role in the study.